Influences of Cross-Border Mobility on Tuberculosis Diagnoses and Treatment Interruption Among Injection Drug Users in Tijuana, Mexico.

• Autores: Robert Deiss, Richard S. Garfein, Remedios Lozada, Jose Luis Burgos, Kimberly C. Brouwer, Kathleen S. Moser, Maria Luisa Zuniga, Timothy C. Rodwell, Victoria D Ojeda, Steffanie Strathdee
• Localización: American journal of public health, ISSN 0090-0036, Vol. 99, Nº. 8, 2009, págs. 1491-1495
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Objectives. We sought to identify correlates of reported lifetime diagnoses of TB among injection drug users in the border city of Tijuana, Mexico. Methods. Injection drug users in Tijuana were recruited into a prospective cohort study during 2006 and 2007. We used weighted multivariate logistic regression to identify correlates of TB diagnoses. Results. Of the 1056 participants, 103 (9.8%) reported a history of TB, among whom 93% received anti-TB medication and 80% were diagnosed in the United States. Treatment was prematurely halted among 8% of patients; deportation from the United States was the cause of half of these treatment interruptions. History of travel to (odds ratio [OR] = 6.44; 95% confidence interval [CI] = 1.53, 27.20) or deportation from (OR = 1.83; 95% CI = 1.07, 3.12) the United States and incarceration (OR = 2.20; 95% CI = 1.06, 4.58) were independently associated with a reported lifetime diagnosis of TB. Conclusions. Mobility and migration are important factors in identifying and treating TB patients diagnosed in the US-Mexico border region. Strengthening capacity on both sides of the border to identify, monitor, and treat TB is a priority. (Am J Public Health. 2009;99:1491-1495. doi:10.2105/AJPH.2008.142166) [ABSTRACT FROM AUTHOR]